Christer Ahlberg discusses HEEALING1 ahead of topline results
In the interview, Christer provides an update on the study and the path towards its next key milestone. HEEALING1 is evaluating Cinclus Pharma’s next-generation potassium-competitive acid blocker (PCAB) in patients with erosive GERD, with topline results expected in the fourth quarter of 2026.
Watch the full interview with Christer Ahlberg on BiotechTV.
The interview was recorded during Swiss Nordic Bio 2026. BiotechTV’s coverage of the conference was presented in partnership with Pareto Securities.